Literature DB >> 28794082

Loss-of-Function KCNE2 Variants: True Monogenic Culprits of Long-QT Syndrome or Proarrhythmic Variants Requiring Secondary Provocation?

Jason D Roberts1, Andrew D Krahn2, Michael J Ackerman2, Ram K Rohatgi2, Arthur J Moss2, Babak Nazer2, Rafik Tadros2, Brenda Gerull2, Shubhayan Sanatani2, Yanushi D Wijeyeratne2, Alban-Elouen Baruteau2, Alison R Muir2, Benjamin Pang2, Julia Cadrin-Tourigny2, Mario Talajic2, Lena Rivard2, David J Tester2, Taylor Liu2, Isaac R Whitman2, Julianne Wojciak2, Susan Conacher2, Lorne J Gula2, Peter Leong-Sit2, Jaimie Manlucu2, Martin S Green2, Robert Hamilton2, Jeff S Healey2, Coeli M Lopes2, Elijah R Behr2, Arthur A Wilde2, Michael H Gollob2, Melvin M Scheinman2.   

Abstract

BACKGROUND: Insight into type 6 long-QT syndrome (LQT6), stemming from mutations in the KCNE2-encoded voltage-gated channel β-subunit, is limited. We sought to further characterize its clinical phenotype. METHODS AND
RESULTS: Individuals with reported pathogenic KCNE2 mutations identified during arrhythmia evaluation were collected from inherited arrhythmia clinics and the Rochester long-QT syndrome (LQTS) registry. Previously reported LQT6 cases were identified through a search of the MEDLINE database. Clinical features were assessed, while reported KCNE2 mutations were evaluated for genotype-phenotype segregation and classified according to the contemporary American College of Medical Genetics guidelines. Twenty-seven probands possessed reported pathogenic KCNE2 mutations, while a MEDLINE search identified 17 additional LQT6 cases providing clinical and genetic data. Sixteen probands had normal resting QTc values and only developed QT prolongation and malignant arrhythmias after exposure to QT-prolonging stressors, 10 had other LQTS pathogenic mutations, and 10 did not have an LQTS phenotype. Although the remaining 8 subjects had an LQTS phenotype, evidence suggested that the KCNE2 variant was not the underlying culprit. The collective frequency of KCNE2 variants implicated in LQT6 in the Exome Aggregation Consortium database was 1.4%, in comparison with a 0.0005% estimated clinical prevalence for LQT6.
CONCLUSIONS: On the basis of clinical phenotype, the high allelic frequencies of LQT6 mutations in the Exome Aggregation Consortium database, and absence of previous documentation of genotype-phenotype segregation, our findings suggest that many KCNE2 variants, and perhaps all, have been erroneously designated as LQTS-causative mutations. Instead, KCNE2 variants may confer proarrhythmic susceptibility when provoked by additional environmental/acquired or genetic factors, or both.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  exome; genetics; long QT syndrome; mutation; prevalence

Mesh:

Substances:

Year:  2017        PMID: 28794082     DOI: 10.1161/CIRCEP.117.005282

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  10 in total

Review 1.  [Genetic testing to prevent sudden cardiac death].

Authors:  B Stallmeyer; S Dittmann; E Schulze-Bahr
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

Review 2.  The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants.

Authors:  Ana I Lopez-Medina; Choudhary Anwar A Chahal; Jasmine A Luzum
Journal:  Pharmacogenomics       Date:  2022-06-14       Impact factor: 2.638

3.  The Hearts in Rhythm Organization: A Canadian National Cardiogenetics Network.

Authors:  Brianna Davies; Jason D Roberts; Rafik Tadros; Martin S Green; Jeffrey S Healey; Christopher S Simpson; Shubhayan Sanatani; Christian Steinberg; Ciorsti MacIntyre; Paul Angaran; Henry Duff; Robert Hamilton; Laura Arbour; Richard Leather; Colette Seifer; Anne Fournier; Joseph Atallah; Shane Kimber; Bhavanesh Makanjee; Wael Alqarawi; Julia Cadrin-Tourigny; Jacqueline Joza; Jimmy McKinney; Stephanie Clarke; Zachary W M Laksman; Karen Gibbs; Vuk Vuksanovic; Martin Gardner; Mario Talajic; Andrew D Krahn
Journal:  CJC Open       Date:  2020-05-29

4.  An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition.

Authors:  Jason D Roberts; S Yukiko Asaki; Andrea Mazzanti; J Martijn Bos; Izabela Tuleta; Alison R Muir; Lia Crotti; Andrew D Krahn; Valentina Kutyifa; M Benjamin Shoemaker; Christopher L Johnsrude; Takeshi Aiba; Luciana Marcondes; Anwar Baban; Sharmila Udupa; Brynn Dechert; Peter Fischbach; Linda M Knight; Eric Vittinghoff; Deni Kukavica; Birgit Stallmeyer; John R Giudicessi; Carla Spazzolini; Keiko Shimamoto; Rafik Tadros; Julia Cadrin-Tourigny; Henry J Duff; Christopher S Simpson; Thomas M Roston; Yanushi D Wijeyeratne; Imane El Hajjaji; Maisoon D Yousif; Lorne J Gula; Peter Leong-Sit; Nikhil Chavali; Andrew P Landstrom; Gregory M Marcus; Sven Dittmann; Arthur A M Wilde; Elijah R Behr; Jacob Tfelt-Hansen; Melvin M Scheinman; Marco V Perez; Juan Pablo Kaski; Robert M Gow; Fabrizio Drago; Peter F Aziz; Dominic J Abrams; Michael H Gollob; Jonathan R Skinner; Wataru Shimizu; Elizabeth S Kaufman; Dan M Roden; Wojciech Zareba; Peter J Schwartz; Eric Schulze-Bahr; Susan P Etheridge; Silvia G Priori; Michael J Ackerman
Journal:  Circulation       Date:  2020-01-16       Impact factor: 29.690

5.  COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.

Authors:  Michael H Gollob
Journal:  J Am Coll Cardiol       Date:  2020-05-11       Impact factor: 24.094

6.  An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome.

Authors:  Arnon Adler; Valeria Novelli; Ahmad S Amin; Emanuela Abiusi; Melanie Care; Eline A Nannenberg; Harriet Feilotter; Simona Amenta; Daniela Mazza; Hennie Bikker; Amy C Sturm; John Garcia; Michael J Ackerman; Raymond E Hershberger; Marco V Perez; Wojciech Zareba; James S Ware; Arthur A M Wilde; Michael H Gollob
Journal:  Circulation       Date:  2020-01-27       Impact factor: 29.690

Review 7.  Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: A review.

Authors:  Aziza El Harchi; Oriane Brincourt
Journal:  J Arrhythm       Date:  2022-06-14

Review 8.  Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2 KCNH2 (hERG) Mutations and Identifying New Patients.

Authors:  Makoto Ono; Don E Burgess; Elizabeth A Schroder; Claude S Elayi; Corey L Anderson; Craig T January; Bin Sun; Kalyan Immadisetty; Peter M Kekenes-Huskey; Brian P Delisle
Journal:  Biomolecules       Date:  2020-08-04

9.  Expression and Localization of Kcne2 in the Vertebrate Retina.

Authors:  Moritz Lindner; Michael J Gilhooley; Teele Palumaa; A Jennifer Morton; Steven Hughes; Mark W Hankins
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-03-09       Impact factor: 4.799

Review 10.  Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population.

Authors:  Estefanía Martínez-Barrios; Sergi Cesar; José Cruzalegui; Clara Hernandez; Elena Arbelo; Victoria Fiol; Josep Brugada; Ramon Brugada; Oscar Campuzano; Georgia Sarquella-Brugada
Journal:  Biomedicines       Date:  2022-01-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.